Tenaya Therapeutics (TNYA) Set to Release Earnings on Wednesday

Tenaya Therapeutics (NASDAQ:TNYA) will likely be issuing its Q3 2026 resultson Wednesday, November 11th. Analysts expect the company to announce earnings of ($0.10) per share and revenue of $0.80 million for the quarter. Investors can find conference call details on the company’s upcoming Q3 2026 earnings report page for the latest details on the call scheduled for Friday, November 13, 2026 at 4:00 PM ET.

Tenaya Therapeutics (NASDAQ:TNYA) last announced its quarterly earnings data on Wednesday, August 5th. The company reported ($0.20) EPS for the quarter, missing analysts’ consensus estimates of ($0.07) by ($0.13). The business had revenue of $1.11 million during the quarter, compared to analysts’ expectations of $10.00 million. On average, analysts expect Tenaya Therapeutics to post ($0.38) EPS for the current fiscal year and ($0.37) EPS for the next fiscal year.

Tenaya Therapeutics Price Performance

NASDAQ:TNYA opened at $0.36 on Wednesday. The stock has a market cap of $82.12 million, a PE ratio of -0.68 and a beta of 2.88. Tenaya Therapeutics has a fifty-two week low of $0.35 and a fifty-two week high of $1.56. The stock’s 50-day moving average is $0.56 and its two-hundred day moving average is $0.71.

Analyst Ratings Changes

Several research firms recently commented on TNYA. Weiss Ratings restated a “sell (d-)” rating on shares of Tenaya Therapeutics in a report on Monday, October 26th. Wall Street Zen raised shares of Tenaya Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Sunday, September 6th. One investment analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, Tenaya Therapeutics has an average rating of “Moderate Buy” and an average target price of $4.00.

About Tenaya Therapeutics

Tenaya Therapeutics, Inc is a clinical-stage biotechnology company focused on developing therapies for genetic and other serious diseases of the heart. The company combines gene therapy, gene editing, cell therapy and small-molecule drug discovery technologies to target the underlying causes of cardiovascular disease rather than treating symptoms alone.

Tenaya’s pipeline has included TN-201, an adeno-associated virus gene replacement therapy being developed for patients with MYBPC3-associated hypertrophic cardiomyopathy, and TN-401, a gene therapy candidate designed for PKP2-associated arrhythmogenic right ventricular cardiomyopathy.